Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | Feb 12, 2020 at 9:50 AM EST

Big Pharma Sees a Rising Tide in Short Interest

The January 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Feb 12, 2020 at 8:45 AM EST

Biotech Short Sellers Focus on a Couple Favorites

The January 31 data has been compared with the previous report, and short interest in most of these selected biotech…

Chris Lange | Feb 11, 2020 at 11:20 AM EST

Is CVS Set to Wow Investors With Q4 Earnings Wednesday Morning?

CVS Health has faced strong headwinds since last year’s acquisition of health insurer Aetna, but its upcoming earnings report could…

Lee Jackson | Feb 11, 2020 at 7:15 AM EST

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid…

Jon C. Ogg | Feb 10, 2020 at 4:35 PM EST

Moderna Commits to $500 Million Capital Raise, With More Possible

Moderna Inc. (NASDAQ: MRNA) had been the biggest biotech initial public offering ever. The company was quite unlucky in the…

Paul Ausick | Feb 10, 2020 at 12:56 PM EST

What the World Health Organization Still Hasn’t Done About Coronavirus

The WHO is convening a meeting Tuesday in Geneva to give researchers and medical practitioners a chance to share information…

Douglas A. McIntyre | Feb 7, 2020 at 1:05 PM EST

When Will Amarin Stock Sell-Off Be Over?

Amarin is a development-stage biotechnology company with one FDA-approved treatment, a cardiovascular disease drug with no real competition. The company…

Chris Lange | Feb 7, 2020 at 11:20 AM EST

Why This Acquisition Could Be Huge for Collegium Pharma

Collegium Pharma shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta…

Chris Lange | Feb 7, 2020 at 10:20 AM EST

AbbVie Wows Again With Q4 Results

AbbVie released better than expected fourth-quarter financial results before the markets opened on Friday.

Chris Lange | Feb 6, 2020 at 12:50 PM EST

PPD Proves Optimistic in IPO Debut

PPD made an exciting entrance to the market Thursday, pricing its shares at the high end of the expected price…

Chris Lange | Feb 6, 2020 at 10:05 AM EST

Why This First of Its Kind Anaphylaxis Treatment Could Be Huge

Aquestive Therapeutics shares jumped on Thursday after the firm announced that it had a constructive face-to-face meeting with the FDA…

Jon C. Ogg | Feb 5, 2020 at 1:20 PM EST

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin…

Chris Lange | Feb 5, 2020 at 10:05 AM EST

Why This FDA Approval Is a Big Win for Vivus

Vivus shares jumped on Wednesday after the company announced a crucial FDA for its supplemental New Drug Application for an…

Chris Lange | Feb 5, 2020 at 9:55 AM EST

Is Merck Stuck in the Slow Lane?

Merck reported fourth-quarter financial results before the markets opened on Wednesday that were essentially in line with expectations, yet shares…

Chris Lange | Feb 4, 2020 at 1:05 PM EST

What to Expect When Merck Reports Before the Opening Bell

Merck is scheduled to release its fourth-quarter financial results before the markets open on Wednesday. Analysts are looking for year-over-year…

1 … 69 70 71 72 73 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Big Pharma Sees a Rising Tide in Short Interest

Biotech Short Sellers Focus on a Couple Favorites

Is CVS Set to Wow Investors With Q4 Earnings Wednesday Morning?

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

Moderna Commits to $500 Million Capital Raise, With More Possible

What the World Health Organization Still Hasn’t Done About Coronavirus

When Will Amarin Stock Sell-Off Be Over?

Why This Acquisition Could Be Huge for Collegium Pharma

AbbVie Wows Again With Q4 Results

PPD Proves Optimistic in IPO Debut

Why This First of Its Kind Anaphylaxis Treatment Could Be Huge

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Why This FDA Approval Is a Big Win for Vivus

Is Merck Stuck in the Slow Lane?

What to Expect When Merck Reports Before the Opening Bell

‘You Bought Stupid Cars You Can’t Afford. You Didn’t Buy a Stupid House.’: Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

'You Bought Stupid Cars You Can't Afford. You Didn't Buy a Stupid House.': Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

‘You Bought Stupid Cars You Can’t Afford. You Didn’t Buy a Stupid House.’: Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

Health and Healthcare Articles

All Health and Healthcare Articles

Big Pharma Sees a Rising Tide in Short Interest

Biotech Short Sellers Focus on a Couple Favorites

Is CVS Set to Wow Investors With Q4 Earnings Wednesday Morning?

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

Moderna Commits to $500 Million Capital Raise, With More Possible

What the World Health Organization Still Hasn’t Done About Coronavirus

When Will Amarin Stock Sell-Off Be Over?

Why This Acquisition Could Be Huge for Collegium Pharma

AbbVie Wows Again With Q4 Results

PPD Proves Optimistic in IPO Debut

Why This First of Its Kind Anaphylaxis Treatment Could Be Huge

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Why This FDA Approval Is a Big Win for Vivus

Is Merck Stuck in the Slow Lane?

What to Expect When Merck Reports Before the Opening Bell

‘You Bought Stupid Cars You Can’t Afford. You Didn’t Buy a Stupid House.’: Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

Featured Reads

'You Bought Stupid Cars You Can't Afford. You Didn't Buy a Stupid House.': Dave Ramsey to Spokane Caller Sitting on $900K Inherited Home and $100K in Debt

This $575,000 Portfolio Pays More Cash Every Month Than $1 Million in the S&P 500